Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Pacira BioSciences's Sloan Ratio for the quarter that ended in Jun. 2026 was -21.24%.
As of Jun. 2026, Pacira BioSciences has a Sloan Ratio of -21.24%, indicating there is a warning stage of accrual build up.
Pacira BioSciences (FRA:82P) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Pacira BioSciences has a Sloan Ratio of -21.24%, indicating there is a warning stage of accrual build up.
Pacira BioSciences Sloan Ratio % Related Terms
Pacira BioSciences Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ALVO, BIOA, COLL: Sloan Ratio % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Sloan Ratio % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Pacira BioSciences's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Pacira BioSciences's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 4.628 (Sep. 2025 ) + 1.398 (Dec. 2025 ) + 2.522 (Mar. 2026 ) + 4.039 (Jun. 2026 ) = €12.6 Mil.
Pacira BioSciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 51.831 (Sep. 2025 ) + 37.31 (Dec. 2025 ) + 22.213 (Mar. 2026 ) + 49.875 (Jun. 2026 ) = €161.2 Mil.
Pacira BioSciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was 37.159 (Sep. 2025 ) + 16.51 (Dec. 2025 ) + 16.816 (Mar. 2026 ) + 10.207 (Jun. 2026 ) = €80.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a Sloan Ratio % of -21.24% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Sloan Ratio % too high?
Pacira BioSciences' current Sloan Ratio % is -21.24%. Overall, Pacira BioSciences has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Sloan Ratio % compare to ALVO and BIOA?
Pacira BioSciences' Sloan Ratio % of -21.24% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Sloan Ratio % is -21.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Sloan Ratio % of -21.24%. The stock's GF Value™ is €24.40, compared to a current price of €21.60 — trading 11.5% below its estimated fair value. The current Sloan Ratio % is -21.24%. Pacira BioSciences' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Sloan Ratio % is -21.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €21.60 is trading 11.5% below its estimated GF Value™ of €24.40.
Key valuation signals for FRA:82P:
Sloan Ratio %: -21.24%
GF Value™: €24.40 vs. price of €21.60 (11.5% below fair value)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
83GF Score
Get the complete analysis for FRA:82P
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
